reviewJNCI Journal of the National Cancer InstituteJun 19, 2002BRONZE OA

Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us

Harvard University · Dana-Farber Cancer Institute

PubMed
Indexed incrossrefpubmed

Abstract

A substantial number of clinical trials using antiangiogenic therapies are ongoing worldwide. How to achieve the maximum benefit from these therapies and how to monitor patient response are of paramount concern to investigators. There are currently no markers of the net angiogenic activity of a tumor available to aid investigators in the design of antiangiogenic treatment schemes. It stands to reason that quantification of various aspects of tumor vasculature might provide an indication of angiogenic activity. One often-quantified aspect of tumor vasculature is microvessel density. Studies over the last decade have demonstrated the value of using tumor microvessel density as a prognostic indicator for a wide…

Citation impact

786
total citations
FWCI
16.56
Percentile
100%
References
139
Citations per year

Authors

1

Topics & keywords

Keywords
  • Microvessel
  • Antiangiogenic therapy
  • Context (archaeology)
  • Medicine
  • Clinical trial
  • Surrogate endpoint
  • Angiogenesis
  • Pathology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.